Amorphex Therapeutics

Amorphex Therapeutics is an ophthalmic drug delivery company advancing its proprietary TODDD™ platform, a soft device worn under the eyelid for sustained, continuous drug release. The technology addresses critical shortcomings of topical eye drops, including poor patient adherence, inconsistent dosing, and side effects from preservatives. Founded by a team with a successful track record in ophthalmic product development, the company is currently in the preclinical stage, seeking clinical funding and strategic partnerships to advance its pipeline targeting glaucoma, retinal diseases, and myopia progression.

TODDD™ (Therapeutic Ocular Drug Delivery Device): A patented, soft, non-invasive ocular insert worn under the eyelid. It uses controlled-release polymer systems to deliver drugs continuously for 3 to 90+ days, addressing poor adherence and dosing inaccuracies of eye drops.

Amorphex competes in the sustained-release ocular drug delivery space with companies like Ocular Therapeutix (Dextenza insert), Santen (various devices), and Alimera Sciences (Iluvien implant). Differentiation hinges on TODDD™'s specific design (under eyelid, soft, multi-month duration), comfort, and its platform flexibility for multiple drugs and indications.